Sividon Diagnostics GmbH
Second-generation gene expression tests for breast cancer compared: EndoPredict und PAM50
In a comparison of the established gene expression test EndoPredict and variants of the PAM50-Risk-of-Recurrence test, the Spanish GEICAM-research group concludes that EndoPredict (EPclin) provides more prognostically relevant information than PAM50. The results are based on direct comparison of the two tests within the GEICAM/9906 study. The results have now been published in the journal Breast Cancer Research and Treatment. Gene expression tests are used in breast cancer patients in order to support an unambiguous decision for or against chemotherapy. This is accomplished by a precise characterization of molecular processes in the tumour. Patients with a good prognosis can be treated without chemotherapy without compromising their chances for recovery and survival. Both EndoPredict and PAM50 are second-generation tests. These tests account for tumour biology combined with clinical factors to allow for improved treatment decisions. This makes the prognosis more reliable than older tests, which rely solely on tumour biology. In addition to tumour biology, PAM50 (ROR-PT) considers tumour size, while EndoPredict accounts for tumour size and nodal status along with tumour biology. In the GEICAM/9906 study, disease-free survival of low-risk patients after 10 years was 92% according to PAM50 (ROR-PT); it was 100% according to EndoPredict. In the study, both EndoPredict and PAM50 were superior to a stratification of patients based on purely clinical-pathological information, while EndoPredict-based analyses lead to better results than all PAM50-variants. In a comparison of all prognostic factors, only the EndoPredict test (EPclin) provided additional prognostic information to all other factors. Source: http://link.springer.com/article/10.1007/s10549-016-3725-z EndoPredict is a gene expression test to determine the prognosis of patients with breast cancer. Patients with very good prognosis may generally do without stressful chemotherapy. EndoPredict is particularly useful for those women whose tumour belongs to the intermediate-risk group according to classical criteria. Sividon Diagnostics GmbH was founded in July 2010 as a management buyout of Siemens Healthcare Diagnostics Products at the Cologne location. The company’s mission is to sustainably increase the quality of therapy-accompanying diagnostics in oncology. Since 2011, with the EndoPredict(R) the first diagnostic test by Sividon has been available. More information can be found at www.sividon.com or www.endopredict.com
End of Media Release Issuer: Sividon Diagnostics GmbH Key word(s): Health
2016-03-22 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. |